Myeloid Cell Targeting Therapeutics Market

Myeloid Cell Targeting Therapeutics Market by Type of Molecule, Therapeutic Area, Route of Administration and Geography (North America, Europe and Asia Pacific), 2021-2035

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    0

  • Pages
    212

  • View Count
    9879

Myeloid Cell Targeting Therapeutics Market Overview

The myeloid cell targeting therapeutics market is estimated to be worth $652 million in 2022 and is expected to grow at CAGR of over 40% during the forecast period. With over 19 million new cancer cases and 10 million deaths reported in the year 2020, the global cancer burden continues to increase rapidly.

Given the rising prevalence, researchers have made significant efforts in discovering new approaches for the treatment of oncological diseases. With several programs having entered the clinical stages, myeloid cells targeting therapeutics have emerged as a novel strategy in the suite of cancer immunotherapy approaches. Myeloid cells represent a group of cells containing granulocytes, monocytes, macrophages, mast cells and dendritic cells, which play a key role in innate immunity. These cells are found in abundance in the tumor microenvironment and inflamed areas.

The tumor recruits and modulates endogenous myeloid cells to tumor-associated macrophages, dendritic cells, myeloid-derived suppressor cells and neutrophils, to sustain an immunosuppressive environment. Over time, many research studies have shown that myeloid cells can interact with the immune system and aid in generating an appropriate anti-tumor immune response. Targeting these cells help in modulating cancer-associated activities, including immune evasion. Therefore, myeloid therapies have gained significant attention as a potential adjunct to currently used therapies, such as immune checkpoint inhibitors, dendritic cell vaccines, oncolytic viruses, and chemoradiation to enhance therapeutic response. In addition, myeloid cell targeting therapies are being investigated for their potential in the treatment of various inflammatory disorders. 

Presently, several medical researchers and industry stakeholders are engaged in the development of therapeutics targeting myeloid cells that harness the immune system in order to treat a number of solid tumors, leukemias and some rare conditions, including myelodysplastic syndrome and ANCA-associated vasculitis. The substantial data from the ongoing studies and completed trials suggest that targeting of myeloid cells results in the delayed progression of solid tumors, thereby increasing the survival rate of the patients. Given the encouraging results, the domain has attracted the attention of many private and public investors who have invested around USD 4.9 billion over the last few years. Driven by the increasing R&D activity, promising clinical data and financial support from investors, the myeloid cell targeting therapeutics market is anticipated to witness a commendable market growth during the forecast period.

This image provides list of Myeloid Cells Targeting Therapeutics Presently, over 40 companies worldwide have taken initiatives to develop drug therapies targeting myeloid cells; the market is characterized by a mix of well-established and small firms This image presents current market landscape of Myeloid Cells Targeting Therapies. The pipeline features 115+ myeloid cells targeting therapies that are currently being evaluated across different phases of development; most of these are designed for intravenous administration This image presents review of close to 10,000 peer-reviewed, scientific articles related to Myeloid Cells Targeting Therapeutics. Over 10,000 articles, indicative of the ongoing research and innovation in this field, have been published in scientific literature; key focus of such studies is on the development of anti-tumor therapeutics

Key Companies in Myeloid Cell Targeting Therapeutics Market

Examples of key companies engaged in myeloid cell targeting therapeutics market (which have also been profiled in this market report; the complete list of companies is available in the full report) include ChemoCentryx, Daiichi Sankyo, Gilead Sciences, Janssen Biotech, Roche, Pfizer, GlaxoSmithKline, Macrophage Pharma, Enlivex, Immune-Onc Therapeutics, Infinity Pharmaceuticals and AstraZeneca. This market report includes an easily searchable excel database of all the companies developing therapeutics targeting myeloid cells, worldwide.

Recent Developments in Myeloid Cell Targeting Therapeutics Market:

Several recent developments have taken place in the field of myeloid cell targeting therapeutics market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In August 2023, XNK Therapeutics entered into a research collaboration with the Karolinska University Hospital to evaluate the suitability of the company's autologous natural killer cell therapy candidate, XNK02, as a novel therapy for treatment of acute myeloid leukemia. 
  • In August, the FDA granted Orphan Drug Designation to Faron Pharmaceuticals’ bexmarilimab used for the treatment of patients suffering from acute myeloid leukemia. 
  • In June 2023, Prime Medicine collaborated with Cimeio Therapeutics with an aim to develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for genetic diseases, acute myeloid leukemia and myelodysplastic syndrome.
This image provides information about completed, ongoing and planned clinical studies of Myeloid Cells Targeting Therapeutics. In the past decade, more than 1,500 clinical trials have been registered for evaluating drug therapies targeting myeloid cells; ~380,000 patients have been enrolled till date This image provides information on funding and investments received by players engaged in Myeloid Cells Targeting Therapeutics Market. A variety of investors, having realized the benefits and future opportunity, have invested over USD 5 billion across more than 70 instances, since 2017 This image provides information on grants that have been awarded to research institutes engaged in conducting projects related to Myeloid Cells Targeting Therapeutics. Over 4,000 academic grants have also been awarded to several organizations to financially support the ongoing efforts for research and innovation in this domain

Scope of the Report

The “Myeloid Cell Targeting Therapeutics Market by Type of Molecule (Small Molecule and Biologics), Therapeutic Area (Oncological Disorders and Rare Disorders), Route of Administration (Intravenous and Oral) and Geography (North America, Europe and Asia Pacific), 2021-2035” market report offers an extensive study on the current market landscape, market size, market share, market forecast, market outlook and future opportunities of the myeloid cell targeting therapeutics market. The market research report underlines an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in myeloid cell targeting therapeutics market.

In addition to other elements, the market research report includes:

  • A detailed assessment of the current market landscape of myeloid cells targeting therapeutics, based on several relevant parameters, such as phase of development (clinical and preclinical), type of molecule (small molecules and biologics), target indication, therapeutic area (oncological disorders, hepatic disorders, autoimmune disorders, inflammatory diseases, respiratory disorders, neurological disorders, renal disorders, rheumatological disorders, immunological disorders and others), biological target, route of administration (intravenous, oral, subcutaneous, intratumoral, nasal and others), type of therapy (monotherapy and combination therapy), combination drug, line of treatment and dosing frequency. In addition, it provides details on the companies engaged in the development of myeloid cells targeting therapeutics, along with information on their year of establishment, company size and location of headquarters.
  • Elaborate profiles of key players engaged in the development of myeloid cells targeting therapeutics. Each profile features a brief overview of the company, details on its drug candidates, its financial information (if available), recent developments and an informed future outlook.
  • A detailed analysis of completed and ongoing clinical trials of various myeloid cells targeting therapeutics, based on different parameters, such as trial status, trial registration year, type of sponsor / collaborator, study design, number of patients enrolled. In addition, the chapter highlights year-wise trend of completed and recruiting trials, age category of the patients enrolled, active industry and non-industry players and location of the trials.
  • A detailed review of more than 10,000 peer-reviewed, scientific articles related to research on myeloid cells targeting therapeutics, based on parameters, such as year of publication, emerging focus area, type of publication, therapeutic area, and target indication. The chapter also highlights the top journals and top authors (in terms of number of articles published).
  • An in-depth analysis of academic grants that have been awarded to various research institutes for projects related to myeloid cell targeting therapeutics, during the period, 2017-2021, based on several parameters, such as year of grant award, amount awarded, type of funding institute center, popular NIH departments, support period, emerging focus area, purpose of grants, grant activity code, local recipients, type of recipient organization study section and type of grant application. Further, the chapter also highlights the popular recipient organizations, (in terms of number of grants and amount awarded) and prominent program officers.
  • An analysis of the partnerships that have been established in myeloid cell targeting therapeutics market since 2017, covering instances of  research and development agreement, clinical trials agreement, merger / acquisition, product development and commercialization agreement, licensing agreement, asset acquisition and product development and manufacturing agreement. 
  • A detailed analysis of the various investments made since 2017, including grants, seed financing, venture capital financing, IPOs, secondary offering, other equity, post IPO equity and equity crowdfunding in the companies focused on the development of myeloid cells targeting therapeutics.
  • An analysis of start-ups / small companies engaged in the development of myeloid cells targeting therapeutics, based on parameters, such as pipeline strength, pipeline maturity, indication diversity, financial support, number of investors, partnership activity and start-up health indexing.
  • A case study on the companies developing macrophage-based therapeutics, along with analyses on phase of development, type of molecule, target indication and therapeutic area. In addition, the chapter provides information on the year of establishment, company size and location of headquarters of the companies engaged in the development of these therapeutics.
This image provides list of Macrophage-based Therapeutics Developers. 20+ macrophage-based therapeutics are being developed by various industry and non-industry players; majority of these are intended for the treatment of oncological disorders This image highlights the start-up established in the domain of myeloid cells targeting therapeutics. Several well funded start-ups have entered this domain; our proprietary start-up health indexing analysis confirms the presence of a number of players that offer significant promise This image highlights the market segments of Myeloid Cells Targeting Therapeutics. With two approved therapeutics and a growing development pipeline, we anticipate the overall market to witness an annualized growth of over 40% in the coming decade

The key objective of myeloid cell targeting therapeutics market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for myeloid cell targeting therapeutics market during the forecast period. Based on parameters, such as adoption trends, and expected price variations for these products, we have developed informed estimates on the evolution of the market for the forecast period 2021-2035. Our year wise projections of the current and forecasted opportunity within the myeloid cell targeting therapeutics market, have further been segmented across [A] type of molecule (small molecule and biologics), [B] therapeutic area (oncological disorders and rare disorders), [C] route of administration (intravenous and oral route) and [D] geography (North America, Europe and Asia Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the market report were influenced by discussions held with several stakeholders in myeloid cell targeting therapeutics market. The market report features detailed transcripts of interviews held with the following individuals:

  • Rene Hoet (Chief Scientific Officer, Montis Biosciences)
  • Tom Wilton (Chief Business Officer, Carisma Therapeutics)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What are myeloid cell therapeutics?

Answer: Myeloid cell therapeutics is based on targeting myeloid cells and helping in modulating cancer-associated activities, including immune evasion. Myeloid cell therapeutics have gained significant attention as a potential adjunct to currently used therapies, such as immune checkpoint inhibitors, dendritic cell vaccines, oncolytic viruses, and chemoradiation to enhance therapeutic response.

Question 2: How big is the myeloid cell targeting therapeutics market?

Answer: The myeloid cell targeting therapeutics market size is estimated to be worth $652 million in 2022.

Question 3: What is the projected market growth of the myeloid cell therapeutics market?

Answer: The myeloid cell targeting therapeutics market is expected to grow at compounded annual growth rate (CAGR) of over 40% during the forecast period 2021 - 2035.

Question 4: Who are the leading players in the myeloid cell targeting therapeutics market?

Answer: Examples of key companies engaged in myeloid cell targeting therapeutics market (which have also been profiled in this market report; the complete list of companies is available in the full report) include ChemoCentryx, Daiichi Sankyo, Gilead Sciences, Janssen Biotech, Roche, Pfizer, GlaxoSmithKline, Macrophage Pharma, Enlivex, Immune-Onc Therapeutics, Infinity Pharmaceuticals and AstraZeneca.

Question 5: How many companies are currently engaged in the myeloid cell targeting therapeutics market?

Answer: Over 40 companies are currently engaged in the myeloid cell targeting therapeutics market.

Question 6: How many drug candidates are presently under development by stakeholders engaged in the myeloid cell targeting therapeutics market?

Answer: Over 110 drug candidates are presently under development by stakeholders engaged in the myeloid cell targeting therapeutics market.

Question 7: Which region is the hub for companies engaged in the myeloid cell targeting therapeutics market?

Answer: North America emerged as the hub for companies engaged in the myeloid cell targeting therapeutics market, with close to 65% of the players established in the region.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com